Martin Shkreli Isn’t the Only Profiteer in the Pharmaceutical Industry: Why Does the U.S., Alone Among Developed Countries, Allow Life-Saving Prescription Drugs To Be Priced Beyond the Reach Of Many Of the Patients Who Need Them? David Brushwood, professor emeritus of Pharmaceutical Outcomes and Policy at the University of Florida College of Pharmacy returns to Democratic Perspective to talk about price gouging in the pharmaceutical industry — how it got started, who benefits from it and who doesn’t, and what can be done about it. As it turns out, the U.S. government already has many of the tools it needs to make drugs available at a reasonable price to everyone. What it lacks is the will to use them.
Podcast: Play in new window | Download
Subscribe: Apple Podcasts | RSS